Author: healthadmin

Clinically available KRAS inhibitors primarily target G12C, which is rare in PDAC and often develops resistance. Oncogenic KRAS inactivates RB1 through CDK4/6, but RB1 mutations are rare. Therefore, CDK4/6 inhibition provides an indirect strategy to combat KRAS-mediated malignancies without directly targeting KRAS. Virtually all pancreatic ductal adenocarcinomas (PDACs) result from activating mutations in the oncogene KRAS, which occurs in multiple different allelic forms. Although significant efforts have been made to develop inhibitors that target specific mutant KRAS proteins, the only drugs currently approved for clinical use are those that selectively target the KRASG12C variant. However, KRASG12C mutations are extremely rare…

An international team of researchers has achieved a breakthrough in the production of doxorubicin, an important chemotherapy agent. This research identifies and resolves a molecular “bottleneck” that has limited the drug’s natural production for more than 50 years. Doxorubicin is a chemotherapy drug that was first approved for medical use in the 1970s. It is the basis of treatment for a variety of cancers, including breast cancer, bladder cancer, lymphoma, and carcinoma, and more than 1 million patients are treated annually. However, bacteria naturally produce this important drug very inefficiently. As a result, the pharmaceutical industry has relied on expensive…

People under stress can have difficulty orienting themselves in space. Researchers from Bochum have discovered the reason. The stress hormone cortisol disrupts the brain’s navigation system. This impairs the function of grid cells, which play an important role in orientation. This was verified in an imaging study involving 40 people, including researchers at Ruhr University Bochum in Germany. Participants completed a virtual navigation experiment while their brain activity was recorded in an MRI scanner. If the subjects had been given cortisol before the experiment, their performance was even worse, obscuring the exact activity patterns of the grid cells. The results…

Macrophages are at the heart of mechanobiology research. The physical properties of macrophages, namely stiffness, adhesion, and ECM (extracellular matrix) sensing, are closely related to phenotypic polarization and immune function. Pro-inflammatory M1 macrophages typically exhibit higher cell stiffness, whereas anti-inflammatory tissue-repairing M2 macrophages are mechanically more flexible, and these mechanical properties determine how the cell responds to physical cues in the microenvironment. For decades, penstreptomycin has been used at a standard 1% v/v concentration in cell cultures to prevent bacterial contamination, but the effects of penstreptomycin on the mechanophenotype of macrophages, a mechanical property that defines cellular function, had never…

Recent research published in Journal of Applied Social Psychology This suggests that young men have a distorted view of the level of interest that other men have in careers in early childhood education and childcare. The findings provide evidence that sexual orientation stereotypes and misperceptions of peer beliefs further reinforce the shortage of men in caregiving roles. “Globally, men are grossly underrepresented in early childhood education and care. This is problematic for many reasons, but one of the main problems is that it reinforces the idea that care is a ‘women’s job’ (i.e. something that men cannot and should not…

Leading medical organizations on Friday recommended major changes to cardiovascular disease prevention, saying people as young as 40 to 30 should consider statins and other measures to manage cholesterol. Beyond just LDL (“bad”) cholesterol and statins, the latest recommendations take a more comprehensive approach to how and when to prevent and treat cardiovascular disease caused by hardening and narrowing of the arteries. In people without heart disease, if LDL (“bad”) cholesterol levels reach 160 mg/dL or higher starting in young adulthood at age 30, behavioral changes or additional medications are encouraged. That approach starts with a healthier lifestyle and can…

Pfizer CEO Dr. Albert Bourla has yet to surpass the $33 million he earned in 2022 for sales of the company’s COVID-19 blockbuster, but his $27.6 million compensation package isn’t too shabby after a busy 2025. Bourla’s 2025 compensation is his second-highest since taking the helm at Pfizer in 2019, topping last year’s $24.6 million. The CEO is credited with leading the pharmaceutical giant to “solid financial results” and setting the company up for “strong growth” toward the end of the decade, Pfizer said in its proxy statement (PDF). Pfizer had a busy year, with 2025 sales of $62.5 billion,…

For their discovery of genomic imprinting, developmental biologists Davor Salter and Azim Surani will receive the 2026 Paul Ehrlich Ludwig Darmstätter Prize worth 120,000 euros on March 14 at the Paulskirche in Frankfurt. They discovered that we inherit some genes in only one active copy. This is determined by molecular marks that identify maternal or paternal origin, thereby laying the foundation for the field of epigenetics. The Early Career Award goes to neurologist Varun Venkataramani, who helped establish the field of cancer neuroscience by demonstrating that malignant brain tumors use nerve currents to stimulate their growth. A long-standing principle of…

A few weeks ago, I was helping a healthcare organization build data views that would eventually power operational reporting. The team needed a specific metric that I had never worked with before, but no one could immediately point to its source. I turned to the platform’s AI assistant and asked where it lives. This led to some plausible table and column names. I queried the table and the name suggested it might be a good metric. However, three problems quickly became apparent: There was no explanation for the column. A metadata field required to describe the metric was blank. There…

GSK has secured FDA expansion of its respiratory syncytial virus vaccine Aleksby for adults aged 18 to 49 who are at high risk of lower respiratory tract illness caused by the virus. The green light puts GSK on a level playing field with Pfizer and Moderna, which have secured support for RSV vaccinations in 2025 and 2024, respectively. All three vaccinations were originally approved for RSV prophylaxis in adults age 60 and older. In June 2024, GSK received FDA approval for at-risk adults aged 50 and older, and Pfizer achieved an even larger age-at-risk expansion four months later. The FDA’s…